Anzeige
Mehr »
Dienstag, 16.12.2025 - Börsentäglich über 12.000 News
Lithium wird plötzlich knapp: 3% Weltproduktion aktuell weg
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A41BLW | ISIN: KYG0447T1186 | Ticker-Symbol:
NASDAQ
15.12.25 | 21:59
7,090 US-Dollar
0,00 % 0,000
Branche
IT-Dienstleistungen
Aktienmarkt
ASIEN
1-Jahres-Chart
ARB IOT GROUP LIMITED Chart 1 Jahr
5-Tage-Chart
ARB IOT GROUP LIMITED 5-Tage-Chart

Aktueller Chart ARB IOT GROUP Aktie

Chart vergleichen mit:

Firmenname, WKN, ISIN oder Aktien-Kürzel

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%
Chart-Typ:
Zeitraum:
 
ARB IOT GROUP LIMITED-Investoren interessieren sich auch für diese Wertpapiere
Performance Shipping Inc. Announces Delivery of the First of Two 2019-Built Suezmax Tankers, M/T P. Bel AirATHENS, Greece, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Performance Shipping Inc. (NASDAQ: PSHG) ("we" or the "Company"), a global shipping company specializing in the ownership of tanker vessels, announced...
► Artikel lesen
Performance Shipping Inc. Provides Update on Potential Forward Sale Agreement for M/T P. SophiaATHENS, Greece, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Performance Shipping Inc. (NASDAQ: PSHG) ("we" or the "Company"), a global shipping company specializing in the ownership of tanker vessels, today...
► Artikel lesen
Performance Shipping Inc. Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2025ATHENS, Greece, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Performance Shipping Inc. (NASDAQ: PSHG) ("we" or the "Company"), a global shipping company specializing in the ownership of tanker vessels, today...
► Artikel lesen
Taysha Gene Therapies, Inc.: Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett SyndromeThe 2022 Option Agreement between Astellas and Taysha has expired Regaining full rights to TSHA-102 Rett syndrome program enables Taysha to focus on driving its long-term value with full strategic...
► Artikel lesen
Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)DALLAS, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based...
► Artikel lesen
Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett SyndromeBreakthrough Therapy designation granted based on FDA's review of available clinical evidence of safety and efficacy from all 12 patients treated in Part A of the REVEAL Phase 1/2 trials Finalized...
► Artikel lesen